Triton-backed Pharmanovia buys CNS portfolio from Sanofi

• Triton invested in Pharmanovia in 2019
• Pharmanovia is a global lifecycle management healthcare company
• Triton is a European mid-market investor that focuses on industrial tech, services, consumer, and healthcare

Pharmanovia, a portfolio company of Triton Partners, has acquired a portfolio of 11 central nervous system (CNS) medical brands from Sanofi.

The portfolio falls under four therapy areas – psycholeptic, anxiolytic, anti-epileptic, and anti-psychotic.

The acquired brands include Frisium, Sentil, Urbanyl, Urbanil, Urbanol, Urbadan, Noiafren and Castilium.

“Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need,” said James Burt, Pharmanovia CEO.

Triton invested in Pharmanovia in 2019.

Pharmanovia is a global lifecycle management healthcare company based in Basildon, UK.

Triton, based in London, is a European mid-market investor that focuses on industrial tech, services, consumer, and healthcare.

Sanofi, based in Paris is a global healthcare company.